bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR ...
Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites –– Additionally, findings show that verekitug ...
Yatiri Bio Inc. today announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at improving how large-scale proteomics data can be ...
Nabla and Takeda first joined hands in 2022, to push “the boundaries of next-generation biologics discovery,” according to ...
SAN DIEGO--(BUSINESS WIRE)--Rejuvenate Bio, today announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...
U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...
Bio Protocol raises $6.9M in seed funding led by Arthur Hayes’ Maelstrom Fund to expand its decentralised science initiatives.
Researchers from Universiti Tun Hussein Onn Malaysia and Chettinad Institute of Technology developed a Golden Eagle-Assisted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback